Browsing by Author "Lin, Cheng-Jui"

Now showing 1 - 4 of 4

Improvement in Mortality and End-Stage Renal Disease in Patients With Type 2 Diabetes After Acute Kidney Injury Who Are Prescribed Dipeptidyl Peptidase-4 Inhibitors
(2018-12-01)
Chen, Cheng-Yi
;
Wu, Vin-Cent
;
Lin, Cheng-Jui
;
Lin, Chih-Sheng
;
Pan, Chi-Feng
Objective: To focus on the potential beneficial effects of the pleiotropic effects of dipeptidyl peptidase-4 inhibitors (DPP4is) on attenuating progression of diabetic kidney disease in reducing the long-term effect of the acute kidney injury (AKI) to chronic kidney disease (CKD) transition. Patients and Methods: Data from the National Health Insurance Research Database from January 1, 1999, to July 31, 2011, were analyzed, and patients with diabetes weaning from dialysis-requiring AKI were identified. Cox proportional hazards models and inverse-weighted estimates of the probability of treatment were used to adjust for treatment selection bias. The outcomes were incident end-stage renal disease (ESRD) and mortality, major adverse cardiovascular events, and hospitalized heart failure. Results: Of a total of 6165 patients with diabetes weaning from dialysis-requiring AKI identified, 5635 (91.4%) patients were DPP4i nonusers and 530 (8.6%) patients were DPP4i users. Compared with DPP4i nonusers, DPP4i users had a lower risk of ESRD (hazard ratio, 0.81; 95% CI, 0.70-0.94; P=.04) and all-cause mortality (hazard ratio, 0.28; 95% CI, 0.23-0.34; P<.001) after adjustments for CKD, advanced CKD, and angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker use. In contrast, the risk of major adverse cardiovascular events and hospitalized heart failure did not differ significantly between groups. Conclusion: Dipeptidyl peptidase-4 inhibitor users had a lower risk of ESRD and mortality than did nonusers among patients with diabetes after weaning from dialysis-requiring AKI. Therefore, a prospective study of AKI to CKD transitions after episodes of AKI is needed to optimally target DPP4i interventions. (C) 2018 Mayo Foundation for Medical Education and Research
Synthesis of New Blue Anthracene-based Conjugated Polymers and Their Applications in Polymer Light-Emitting Diodes
(2011-06-01)
Shih, Hung-Min
;
Lin, Cheng-Jui
;
Tseng, Shin-Rong
;
Lin, Chih-Hung
;
Hsu, Chain-Shu
A series of anthracene-based conjugated copolymers containing 9,10-bis(6-bromonaphthalen-2- yl)-2-tert-butylanthracene (BNA) and 2,7-diphenyl substituted fluorene (DPPF) moieties are prepared via a palladium-catalyzed Suzuki polymerization. All of the synthesized polymers emit blue light at around 450nm and show good thermal and color stability. Their electro-luminescence spectra remain unchanged at high driving voltage. The double-layer polymer light-emitting diode (PLED) fabricated with ITO/PEDOT: PSS/DPPFBNA3/CsF/Al, produces a maximum brightness of 1 650 cd.m(-2) and has a luminance efficiency of 0.39 cd.A(-1). The ITO/PEDOT: PSS/TFB/DPPFBNA3/CsF/Al multilayer PLED, incorporating a TFB layer to facilitate hole transportation, produces a maximum brightness of 5 371 cd.m(-2) and a luminance efficiency of 1.18 cd.A(-1)
The prevalence and association of chronic kidney disease and diabetes in liver cirrhosis using different estimated glomerular filtration rate equation
(2018-01-05)
Chen, Cheng-Yi
;
Lin, Cheng-Jui
;
Lin, Chih-Sheng
;
Sun, Fang-Ju
;
Pan, Chi-Feng
Background: Chronic kidney disease (CKD) in cirrhosis is one of the dreaded complications associated with a steep rise in mortality and morbidity, including diabetes. There are limited data on the prevalence of CKD and the association with diabetes in outpatients with cirrhosis. Methodology: This is a cross-sectional study of 7,440 adult liver cirrhosis patients enrolled from August 2001 to April 2010 in a medical center. Case control matching by age and sex with 1,967 pairs, and conditional logistic regression for odds of diabetes was analyzed using adjusted model. Results: CKD was present in 46.0%, 45.7% and 45.6% of the study population using the MDRD-6, CKD-EPI and MDRD-4 estimated glomerular filtration rate (eGFR) equations, respectively. Using a conditional logistic regression model after adjusting for other risk factors, odds for diabetes increased significantly compared with non-CKD in CKD stage 3 to 5 (stage 3 similar to 5) based on MDRD-6-adjusted model, ORs were: stage 3 similar to 5, 2.34 (95% CI, 1.78-3.01); MDRD-4-adjusted model, ORs were: stage 3 similar to 5, 8.51 (95% CI, 5.63-11.4); CKD-EPI-adjusted model, ORs were: stage 3 similar to 5, 8.61 (95% CI, 5.13-13.9). Conclusion: In cirrhosis patients, prevalence of diabetes was higher in patients with advanced stage of CKD. For patients with cirrhosis, patients with CKD stages 3 similar to 5 defined by MDRD-4, MDRD-6, and CKD-EPI eGFR equations had increased risk for diabetes. More severe cirrhosis, indicated by the Child-Turcott-Pugh classification was also accompanied by an increased risk for diabetes.
The role of indoxyl sulfate in renal anemia in patients with chronic kidney disease
(2017-10-10)
Wu, Chih-Jen
;
Chen, Cheng-Yi
;
Lai, Thung-S.
;
Wu, Pei-Chen
;
Chuang, Chih-Kuang
Renal anemia is a common complication in patients with advanced chronic kidney disease. In vitro studies have shown that indoxyl sulfate decreases erythropoietin production. Whether this effect is seen in vivo remains unclear. Our goal was to explore the role of indoxyl sulfate in renal anemia. We found serum indoxyl sulfate levels are significantly and negatively associated with erythropoietin levels in human. A multiple stepwise linear regression analyses after adjustment for other independent parameters revealed that free indoxyl sulfate, and total indoxyl sulfate were significantly associated with erythropoietin levels. In animal studies, erythropoietin gene and protein expression were markedly inhibited in rats with chronic kidney disease; however, this effect was significantly reversed by lowering serum indoxyl sulfate with AST-120. Indoxyl sulfate may also inhibit erythropoietin expression in animal models with chronic kidney disease. These findings further support the role of indoxyl sulfate in the development of renal anemia.